2026-06-14T03:44:22Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/184262024-11-28T15:35:12Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16988

00925njm 22002777a 4500 dc Suárez-García, Inés author Perales-Fraile, Isabel author González-García, Andrés author Muñoz-Blanco, Arturo author Manzano, Luis author Fabregate, Martín author Díez-Manglano, Jesús author Fonseca Aizpuru, Eva author Arnalich Fernández, Francisco author García García, Alejandra author Gómez-Huelgas, Ricardo author Ramos-Rincón, José-Manuel author 2021-08-03 Background: Whether immunosuppressed (IS) patients have a worse prognosis of COVID-19 compared to non-IS patients is not known. The aim of this study was to evaluate the clinical characteristics and outcome of IS patients hospitalized with COVID-19 compared to non-IS patients. Methods: We designed a retrospective cohort study. We included all patients hospitalized with laboratory-confirmed COVID-19 from the SEMI-COVID-19 Registry, a large multicentre national cohort in Spain, from March 27th until June 19th, 2020. We used multivariable logistic regression to assess the adjusted odds ratios (aOR) of in-hospital death among IS compared to non-IS patients. Results: Among 13 206 included patients, 2 111 (16.0%) were IS. A total of 166 (1.3%) patients had solid organ (SO) transplant, 1081 (8.2%) had SO neoplasia, 332 (2.5%) had hematologic neoplasia, and 570 (4.3%), 183 (1.4%) and 394 (3.0%) were receiving systemic steroids, biological treatments, and immunosuppressors, respectively. Compared to non-IS patients, the aOR (95% CI) for in-hospital death was 1.60 (1.43–1.79) for all IS patients, 1.39 (1.18–1.63) for patients with SO cancer, 2.31 (1.76–3.03) for patients with haematological cancer and 3.12 (2.23–4.36) for patients with SO transplant. The aOR (95% CI) for death for patients who were receiving systemic steroids, biological treatments and immunosuppressors compared to non-IS patients were 2.16 (1.80–2.61), 1.97 (1.33–2.91) and 2.06 (1.64–2.60), respectively. IS patients had a higher odds than non-IS patients of in-hospital acute respiratory distress syndrome, heart failure, myocarditis, thromboembolic disease and multiorgan failure. Conclusions: IS patients hospitalized with COVID-19 have a higher odds of in-hospital complications and death compared to non-IS patients. 10.1371/journal.pone.0255524 1932-6203 PLOS ONE http://hdl.handle.net/10668/4570 34343222 http://hdl.handle.net/20.500.12105/18426 COVID-19 Spain Odds ratio Myocarditis Hospital mortality Multiple organ failure Heart failure Hematologic neoplasms Prognosis Immunosuppression España Oportunidad relativa Miocarditis Mortalidad hospitalaria Insuficiencia multiorgánica Insuficiencia cardíaca Neoplasias hematológicas Diagnóstico Inmunosupresión In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain